Blockade of transforming growth factor-β-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 2970-2976

  Choo, Min Kyung ^a   Kawasaki, Noritaka ^a   Singhirunnusorn, Pattama ^a   Koizumi, Keiichi ^a   Sato, Shintaro ^b   Akira, Shizuo ^b,c   Saiki, Ikuo ^a   Sakurai, Hiroaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 7 OXOZEAENOL; B LYMPHOCYTE GROWTH FACTOR; CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; ENZYME INHIBITOR; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN C JUN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ANIMALS; APOPTOSIS; CASPASES; DRUG SYNERGISM; FIBROBLASTS; HELA CELLS; HUMANS; MAP KINASE KINASE KINASES; MICE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR RELA; ZEARALENONE;

EID: 33846243774     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0379     Document Type: Article

References (44)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor family. J Biol Chem 1997;271:12687-90.
3. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14: 337-48.
4. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/ TRAIL. Curr Opin Pharmacol 2004;4:333-9.
5. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-72.
6. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
7. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272: 25417-20.
8. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
9. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
10. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-8.
11. Emery JG, McDonnell P, Burke ME, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273: 14363-7.
12. Bodmer JL, Holler N, Reynard S, at al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
13. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611-20.
14. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12: 599-609.
15. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17:1675-85.
16. 2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998;273:33091-8.
17. Yeh WC, Haken R, Woo M, Mak TW. Gene targeting in the analysis of mammalian apoptosis and TNF receptor family signaling. Immunol Rev 1999;169:283-302.
18. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxical Lett 2003;139:89-97.
19. Varfolomeev E, Maecker H, Sharp D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005;280:40599-608.
20. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995;270:2008-11.
21. Sakurai H, Shigemori N, Hasegawa K, Sugita T. TGF-β-activated kinase 1 stimulates NF-κB activation by an NF-κB-inducing kinase-independent mechanism. Biochem Biophys Res Commun 1998;243: 545-9.
22. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor β-activated kinase 1 with IκB kinases to stimulated NF-κB activation. J Biol Chem 1999; 274:10641-8.
23. Sakurai H, Suzuki S, Kawasaki N, at al. Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003;278:36916-23.
24. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999;398:252-6.
25. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000;5:649-58.
26. Irie T, Muta T, Takeshige K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-κB in lipopolysaccharide-stimulated macrophages. FEBS Lett 2000;467:160-4.
27. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004;14:289-301.
28. Shinohara H, Yasuda T, Aiba Y, at al. PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202:1423-31.
29. Wu L, Nakano H, Wu Z. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-κB through TRAF6 and TAK1. J Biol Chem 2006;281:2162-9.
30. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 2005;280:7359-68.
31. Choo MK, Sakurai H, Koizumi K, Saiki I. TAK1-mediated stress signaling pathways are essential for TNF-α-promoted pulmonary metastasis of murine colon cancer cells. Int J Cancer 2006;118:2758-64.
32. Thiefes A, Wolter S, Mushinski JF, et al. Simultaneous blockade of NFκB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor target genes. J Biol Chem 2005;280:27728-41.
33. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
34. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 1999;5: 157-63.
35. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006;84:87-98.
36. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6: 1087-95.
37. Shim JH, Xiao C, Paschal AE, at al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005;19:2668-81.
38. Mizukami J, Takaesu G, Akatsuka H, at al. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 2002;22:992-1000.
39. Van Geelen CMM, de Vries EGE, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2005;7:345-58.
40. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2006; 5:945-51.
41. Wang S, EI-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003;100:15095-100.
42. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
43. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115: 2625-32.
44. MacFarlane M, Cohen GM, Dickens M. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T cells: differential requirements for caspase activation. Biochem J 2000;348:93-101.